Translating Neurology Biomarkers from Research to Potential Clinical Reality

Wednesday, July 29
11:30 a.m. – 12:30 p.m.
Exhibit Hall Theater 1
Presented by Siemens Healthineers

Overview

Join us for a high-impact discussion on how neurology biomarkers progress from discovery to potential future clinical use.

Professor Zetterberg, a pioneer in neurology biomarkers, will share a frontline perspective on biomarker innovation in neurodegenerative diseases, highlighting how candidate biomarkers are identified, prioritized, and validated. Examples include pTau217, BDTau, MTBR-Tau243, and APOE/APOE4.

Dr. Clarke, a leading expert in diagnostics, will focus on the next step: translating promising biomarkers into robust assays designed to be scalable and reproducible. Drawing on real-world experience with neurofilament light chain, he will explore considerations for assay development, implementation, and adoption in translational research settings.

This session helps attendees understand how to address the gap between research innovation and eventual clinical impact.

This session is intended for scientific and educational purposes only. Biomarkers and assays discussed are for research use only and are not intended for diagnostic use.

Moderator

Jim Freeman
Head of Research and Development
Siemens Healthineers

Speakers

Henrik Zetterberg, MD, PhD
Professor and Head of Department, Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, University of Gothenburg, Sweden;
Professor of Neurochemistry, University College London, UK;
Professor of Neurochemistry, University of Wisconsin-Madison, USA

Bill Clarke, PhD
Professor of Pathology
Johns Hopkins University